Alembic Limited Overview
| Metric | FY2024 | FY2025 | FY2026 |
|---|---|---|---|
| Employees (number) | — | 285 | 256 |
FY2024 headcount not publicly disclosed in sources reviewed; FY2026 figure from Morningstar (Zonebourse shows 261).
Alembic Limited is the 1907-founded parent of India's Alembic Group and one of the country's oldest pharmaceutical enterprises. Following the 2010 demerger of its formulations business into Alembic Pharmaceuticals Limited (APL), it has evolved into a hybrid holding-and-operating company with three value pillars. First, an equity-accounted ~28.5% stake in APL — a ₹7,000+ crore-revenue US-generics and India-branded pharma major — which generated ₹191 crore of associate profit in FY2026, roughly 60% of Alembic Limited's consolidated net profit. Second, a Vadodara-centric real estate development and leasing business built on legacy industrial land ("Alembic City"), which contributed 81% of FY2026 operating revenue. Third, a small fermentation- and chemistry-based API manufacturing unit plus captive co-generation/wind power assets. A ~19% stake in phosgene-chemistry specialist Paushak Limited rounds out the portfolio. The stock trades at a pronounced holding-company discount to the market value of its listed stakes.
Company's own description
The company's exchange-filed profile and its website describe Alembic Limited as engaged in pharmaceuticals (Active Pharmaceutical Ingredients), real estate, and power assets (co-generation plants of 11 MW in aggregate and wind power). Its two reportable segments under Ind AS 108 are Active Pharmaceutical Ingredients (API) and Real Estate. Third-party profiles (Morningstar, Simply Wall St) characterise the API segment as manufacturing and marketing fermentation- and chemistry-based APIs, and the real estate segment as constructing residential and commercial projects, providing project management and marketing consultancy, and leasing commercial properties.
Independent characterisation
Alembic Limited is best understood as a promoter-controlled holding company with an operating real-estate tail. Three economic engines drive its reported numbers:
-
Associate income from APL (non-cash in P&L; cash via dividends). Under Ind AS 28, Alembic Limited books its share of APL's profit. In FY2026 this was INR 191.45 crore versus INR 125.93 crore of the company's own (pre-associate) net profit (ScanX summary of FY2026 audited consolidated results). The cash link is APL's dividend: standalone FY2026 dividend receipts were INR 62.95 crore, which almost exactly funded Alembic Limited's own INR 61.41 crore dividend payout (standalone FY2026 cash-flow statement, NSE filing).
-
Real estate (operating cash engine). Revenue is recognised on a completion/transfer basis from residential projects in Alembic City West, Vadodara (townhouses, villas, mid-rise apartments) plus rental income from investment property (INR 299.59 crore carrying value at 31 March 2026) leased in part to group companies such as APL and Alembic City Limited.
-
API (sub-scale manufacturing). FY2026 revenue INR 46.59 crore with standalone segment profit of INR 5.65 crore; a meaningful share of output appears to be sold to APL (standalone sales of goods/services to APL of INR 28.02 crore in H2 FY2026 alone, per the related-party disclosure — this figure also includes rentals and services, so the API-specific portion is not separately disclosed).
Revenue model mix (FY2026, consolidated)
| Revenue type | FY2026 (INR Cr) | Share of revenue (%) | Nature |
|---|---|---|---|
| Real estate (sales of units, leasing, PMC/marketing consultancy) | 193.40 | 80.6 | Project sale + recurring rental + fee |
| API products | 46.59 | 19.4 | Product sales |
| Total revenue from operations | 239.99 | 100.0 | — |
| Other income (dividends, interest, fair-value gains) | 72.97 | n/m | Treasury/investment income |
| Share of associate profit (below PBT) | 191.45 | n/m | Equity-accounted APL profit |
Split between unit-sale revenue and lease rental within the real estate segment is not separately disclosed in the quarterly filings reviewed.
Value-chain position, customers and end-markets
| Business | Value-chain position | Customer types | End-markets |
|---|---|---|---|
| Real estate | Land owner-developer (legacy industrial land), lessor | Affluent/upper-middle households in Vadodara; corporate tenants including group companies | Vadodara (Gujarat) premium residential; commercial leasing |
| API | Bulk-drug manufacturer (upstream of formulations) | Formulators, including the associate APL | Domestic and export pharma (geographic split not disclosed) |
| Power | Captive co-generation (11 MW) and wind | Internal consumption; grid sale not disclosed | Captive |
| Investments | Strategic minority shareholder | — | US generics/India branded pharma (via APL); phosgene chemistry (via Paushak) |
Strategy
Stated strategy
Alembic Limited does not publish investor presentations, earnings-call transcripts or medium-term guidance. Strategic intent must be inferred from filings and capital allocation:
-
Monetise legacy Vadodara land through phased premium residential development. Successive RERA registrations (Townhouse24 2021, The Villas 2022, The Gardens 2023, Park Crescent 2024) show a cadence of roughly one new phase per year, sized at 10–72 units.
-
Build recurring rental income. FY2026 investment property additions of INR 38.41 crore (standalone cash flow) indicate expansion of the leased commercial portfolio.
-
Hold APL as the core long-term asset. No sell-down of the APL stake has been made; the dividend stream funds Alembic Limited's own payout.
-
Maintain the API business as a group-linked operation, with capex in PPE of INR 38.25 crore in FY2026 (allocation between API and real estate not disclosed).
-
Shareholder housekeeping. Investor-servicing initiatives in 2026: "Saksham Niveshak" 100-day campaign for unclaimed dividends (April 2026), special window for physical share dematerialisation, IEPF reminders.
Initiatives in the last 24 months
| Initiative | Date | Detail | Target |
|---|---|---|---|
| Park Crescent construction | 2024–2027 | 72 units; progress 45% by April 2026 | Possession July 2027 |
| The Villas Phase 1 | 2022–2028 | Progress ~56% by April 2026 | Completion August 2028 |
| Leadership transition | Oct 2025 – Jan 2026 | Udit Amin MD; Malika Amin non-executive | — |
| Investment property build-out | FY2026 | INR 38.41 crore additions | — |
| Labour Code compliance | Nov 2025 | INR 1.44 crore provision | — |
| Investor-servicing campaign | Apr 2026 | Second 100-day "Saksham Niveshak" campaign | — |
ESG/sustainability commitments: captive 11 MW co-generation and wind power; CSR via Alembic CSR Foundation (approved INR 1.12 crore; INR 0.56 crore spent in H2 FY2026). No emissions targets disclosed.
Medium-term financial targets/guidance: none issued by Alembic Limited. The associate APL raised FY2027 revenue growth guidance to the mid-teens (from ~10–12%) and US generics guidance to mid-to-high teens after Q1 FY2027 (Multibagg summary of APL earnings call, Aug 2026) — this is the most relevant forward indicator for Alembic Limited's consolidated earnings.
Products & Services
Real Estate segment — project-by-project
| Project | Location | Type & specification | Target customer | RERA / status | Pricing (as listed) | Source |
|---|---|---|---|---|---|---|
| Samsara | Vadodara | Residential (maiden project) | Upper-middle/affluent households | Completed 2014 | — | Kotak company background |
| Veda | Vadodara | Residential | Upper-middle/affluent households | Launched FY2016 | — | Kotak company background |
| Townhouse24 | Behind Bhailal Amin Hospital, Alembic City West, Gorwa | 24 townhouses, 3 blocks × 4 floors, 3 & 4 BHK, 2,659–3,343 sq ft; lift, power backup, yoga room | Affluent families seeking low-density living | RERA PR/GJ/VADODARA/VADODARA/Others/RAA08783/170721; possession date Dec 2025 | Listed INR 35–51 lakh (portal figure; appears inconsistent with unit size) | Gharpe listing |
| The Villas Phase 1 | Alembic City West, Vadodara | RERA describes 10 villas (portal states 22 luxury villas, 4 BHK, double-height terraces) | Luxury segment | RERA PR/GJ/VADODARA/VADODARA/Others/RAA09703 approved 18 Jan 2022; completion due 31 Aug 2028; construction progress 55.92% (Apr 2026) | From INR 80 lakh (portal) | Aurum PropTech; Gharpe |
| The Gardens | Alembic City West, Vadodara | 14 residential flats, carpet area 3,496 sq m | Upper-middle | RERA PR/GJ/VADODARA/VADODARA/Others/RAA12047; status Completed; progress 89.38% (Jan 2026 filing) | — | Aurum PropTech |
| Park Crescent | Alembic City West, Vadodara | 72 apartments, 2 towers × 10 floors, 3.5 & 4.5 BHK, 1,726–2,327 sq ft | Upper-middle families | RERA approved 23 Apr 2024; possession July 2027; progress 36.05% (Jan 2026) → 45.25% (Apr 2026) | Listed INR 22–30 lakh (portal) | Aurum PropTech; Gharpe |
| Commercial leasing portfolio | Alembic Road / Alembic City, Vadodara | Investment property carrying value INR 299.59 crore (31 Mar 2026); additions of INR 38.41 crore in FY2026 | Corporate tenants incl. APL, Alembic City Ltd | Operating | Lease rentals; not disclosed | FY2026 standalone balance sheet & cash flow |
| Project management & marketing consultancy | Vadodara | Fee-based services to group/related entities | Related parties | Operating | Fee; not disclosed | Morningstar/Simply Wall St profiles |
Total project costs per RERA: The Villas Phase 1 INR 64.65 crore; The Gardens INR 36.61 crore. Aggregate unsold inventory, booking values and collections are not publicly disclosed by the company (no investor presentation is published).
API segment
| Offering | Description | Customer | Detail available |
|---|---|---|---|
| Fermentation-based APIs | Bulk actives produced via fermentation — the company's historical core competency | Formulators incl. APL | Molecule list not publicly disclosed in sources reviewed |
| Chemistry-based APIs | Synthetic bulk actives | Formulators | — |
| Manufacturing sites | Vadodara (Gujarat) | — | Kotak Securities |
FY2026 API revenue was INR 46.59 crore (+44.6% YoY), the strongest growth in at least five years, with a standalone segment profit of INR 5.65 crore (12.1% margin). Q4 FY2026 API, however, swung to a segment loss of INR 1.17 crore (standalone FY2026 Q4 filing), indicating volatile utilisation.
Power assets
| Asset | Specification | Use |
|---|---|---|
| Co-generation plants | 11 MW aggregate | Captive steam/power for Vadodara operations |
| Wind power | Capacity not disclosed | Captive/grid (not disclosed) |
Strategic investments (portfolio "products" of the holding company)
| Holding | Shares held | Stake | Business | Accounting |
|---|---|---|---|---|
| Alembic Pharmaceuticals Ltd | 56,097,544 | ~28.4–28.5% | Integrated pharma: US generics (185 commercialised US products as of Q1 FY2027), India branded formulations, ex-US, API | Equity method (associate); cost INR 86.65 crore |
| Paushak Ltd | 4,702,472 (post 1:2 split and 3:1 bonus) | ~19.0–19.1% | India's largest phosgene-based specialty chemicals maker (14,400 TPA phosgene plant) | Fair value through OCI; INR 162.52 crore at 31 Mar 2026 |
Financial Narrative
Basis: consolidated unless stated. FY2021–FY2025 line items from Research360 (aggregator, based on filed consolidated statements); FY2024–FY2026 headline figures cross-checked against company filings.
Income statement (INR crore)
FY2026 total income: INR 312.96 crore per ScanX (company figure); Fyers reports INR 313.27 crore — minor discrepancy. FY2023 and FY2024 net profit incl. associate are aggregator figures (Zerodha) and could not be reconciled to primary filings.
Per-share data
Consolidated EPS computed as net profit incl. associate ÷ 256.78 million shares (no dilutive instruments disclosed). FY2026 standalone EPS of INR 4.85 is as filed.
Margins and growth
Revenue CAGR FY2021–FY2026: 26.7% (73.52 → 239.99). Revenue CAGR FY2023–FY2026: 23.7%.
Gross profit is not meaningful as reported: real-estate cost of construction (INR 60.02 crore standalone FY2026) and API material cost (INR 13.88 crore plus INR 2.55 crore inventory change) are both shown as expenses. Approximate standalone gross profit for FY2026 = 231.93 − 13.88 − 2.55 − 60.02 = INR 155.48 crore (67.0%), computed from the NSE FY2026 standalone filing.
Balance sheet (standalone, 31 March 2026, INR crore)
Source: NSE Integrated Filing (standalone, FY2026). Multi-year balance sheet history: consolidated net debt INR 10.08 crore at March 2025 (Zerodha, aggregator).
Cash flow (standalone FY2026, INR crore)
Observation: the standalone cash-flow statement presents dividend income as an operating-to-investing reclassification; OCF of INR 117.40 crore included a INR 47.15 crore release from inventories (real-estate deliveries).
Commentary — trends, inflections, drivers
Revenue inflection (FY2023–FY2025). Revenue nearly tripled between FY2022 (INR 78 crore) and FY2025 (INR 222 crore), driven almost entirely by real estate, which rose from INR 46 crore to INR 190 crore as Townhouse24, The Gardens and earlier Alembic City phases were delivered and recognised. FY2026 growth slowed to 8.2% as real estate plateaued (+2.0%) — consistent with a gap between the completion of earlier phases and the handover of Park Crescent (due July 2027) and The Villas (due August 2028). Q1 FY2027 revenue of INR 48.74 crore (−2.0% YoY) confirms the lull.
Margin peak and normalisation. EBITDA margin (excluding other income) expanded from 15% in FY2021 to a peak of 42% in FY2025, as high-margin land-based real-estate revenue scaled against a largely fixed employee base. It eased to ~37% in FY2026 because the API mix rose (lower margin) and Q3 FY2026 absorbed a INR 1.44 crore Labour Code provision.
Earnings quality. Other income (chiefly APL dividends) has averaged INR 60–90 crore annually since FY2022 and routinely exceeds operating EBITDA. Consolidated net profit is dominated by associate income: in FY2026 APL contributed INR 191.45 crore of the INR 317.38 crore total (60%). Alembic Limited's earnings therefore track APL's earnings cycle more than its own operations.
Balance sheet. The company is effectively debt-free (gross debt INR 10.64 crore), with INR 89 crore of current investments. Capital deployment in FY2026 shifted toward investment property and PPE (INR 76.65 crore combined, versus OCF of INR 117.40 crore), signalling a build-out of the leasing portfolio.
OCI volatility. Standalone FY2026 OCI was −INR 94.65 crore, driven by a fair-value decline in equity instruments (items not reclassified to P&L −INR 103.63 crore pre-tax), most plausibly the Paushak stake whose carrying value fell from INR 416.02 crore to INR 162.52 crore over the RPT reporting period. The magnitude of the decline exceeds the full-year OCI charge, implying that part of the movement may reflect valuation timing or a partial disposal; the filing does not reconcile this, and it is flagged as not fully verified.
Unlock Company Financials
Unlock this company profile to view its financial data.
View Subscription PlansFinancial Detail
Group Entities
| Entity | Relationship to Alembic Limited | Role | Source |
|---|---|---|---|
Nirayu Private Limited | Holding company (promoter) | Principal promoter vehicle | FY2026 RPT disclosure |
Alembic Limited | Listed parent of operating businesses | API, real estate, power, investments | — |
Alembic City Limited | Wholly owned subsidiary | Real-estate/leasing related; recipient of corporate guarantee | FY2026 RPT disclosure |
Alembic Pharmaceuticals Limited | Associate (~28.4–28.5%) | Formulations & API pharma major | FY2026 RPT; Zonebourse |
Paushak Limited | Investee (~19.1%), promoter-group company; carried at fair value | Phosgene-based specialty chemicals | Zonebourse; FY2026 RPT |
Shreno Limited / Shreno Engineering Limited | Promoter-group companies | Engineering, real estate undertaking (post-2019 scheme) | FY2026 RPT |
Alembic CSR Foundation | Other related party | CSR execution | FY2026 RPT |
Segment Overview
| Segment | Contents | Products/services |
|---|---|---|
Active Pharmaceutical Ingredients (API) | Bulk drug manufacturing | Fermentation- and chemistry-based APIs (molecule list not publicly disclosed in sources reviewed) |
Real Estate | Development, leasing, consultancy | Residential projects (townhouses, villas, apartments), commercial leasing, project management & marketing consultancy |
Segment revenue (INR Cr)
| Segment revenue (INR Cr) | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 | FY2026 |
|---|---|---|---|---|---|---|
Real Estate | 45.0 | 46.0 | 101.0 | 125.74 | 189.67 | 193.40 |
API | 28.5 | 32.3 | 26.5 | 31.75 | 32.22 | 46.59 |
Total revenue from operations | 73.52 | 78.22 | 127.24 | 157.49 | 221.89 | 239.99 |
Revenue by Segment (%) and Segment Margins & Growth (%)
| Metric | FY2022 | FY2023 | FY2024 | FY2025 | FY2026 |
|---|---|---|---|---|---|
Real Estate share of revenue (%) | 58.8 | 79.4 | 79.8 | 85.5 | 80.6 |
API share of revenue (%) | 41.3 | 20.8 | 20.2 | 14.5 | 19.4 |
Real Estate YoY growth (%) | 2.2 | 119.6 | 24.5 | 50.8 | 2.0 |
API YoY growth (%) | 13.3 | -18.0 | 19.8 | 1.5 | 44.6 |
Revenue by Segment
| Segment result (INR Cr) | FY2024 | FY2025 | FY2026 |
|---|---|---|---|
Real Estate — consolidated | 51.26 | 88.06 | — |
Real Estate — standalone | — | 83.90 | 78.59 |
API — standalone | — | — | 5.65 |
Unlock Company Financials
Unlock this company profile to view its financial data.
View Subscription PlansSegment margin (%)
| Segment margin (%) | FY2024 | FY2025 | FY2026 |
|---|---|---|---|
Real Estate margin, consolidated | 40.8 | 46.4 | — |
Real Estate margin, standalone | — | 46.1 | 42.4 |
API margin, standalone | — | — | 12.1 |
Segment Assets & Liabilities
| Segment balance (INR Cr) | Mar-2024 | Mar-2025 | Dec-2025 | Mar-2026 (standalone) | Jun-2026 |
|---|---|---|---|---|---|
Real Estate segment assets | 367.00 | 443.13 | 489.18 | 501.65 | 528.73 |
Real Estate segment liabilities | 76.82 | 99.47 | 80.60 | 71.90 | 77.65 |
API segment assets | — | — | — | 180.81 | — |
Total segment assets | — | — | 673.18 | 682.46 | 711.01 |
Revenue History
| Quarter | Revenue | Real Estate | API (derived) | PBT | Net profit incl. associate |
|---|---|---|---|---|---|
Q1 FY2026 (Jun-25) | 49.75 | 36.80 | 12.95 | 19.78 | 61.64 |
Q2 FY2026 (Sep-25) | 55.86 | 45.56 | 10.30 | 84.78 | 128.49 |
Q3 FY2026 (Dec-25) | 74.34 | 60.84 | 13.50 | 25.76 | 60.12 |
Q4 FY2026 (Mar-26) | 60.04 | 50.21 | 9.83 | 18.43 | 67.13 |
Q1 FY2027 (Jun-26) | 48.74 | 37.03 | 11.71 | 17.34 | 64.89 |
Income Statement
| Metric (INR Cr) | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 | FY2026 |
|---|---|---|---|---|---|---|
Revenue from operations | 73.52 | 78.22 | 127.24 | 157.49 | 221.89 | 239.99 |
Other income | 10.27 | 89.18 | 64.26 | 54.77 | 74.89 | 72.97 |
Total income | 83.79 | 167.40 | 191.50 | 212.26 | 296.78 | 312.96 |
Operating profit / EBITDA excl. other income | 11.07 | 13.93 | 40.33 | 56.87 | 93.71 | 89.37 |
Depreciation | 3.94 | 4.86 | 6.72 | 7.84 | 10.63 | 12.01 |
Finance cost | 0.36 | 0.39 | 0.47 | 1.11 | 2.47 | 1.57 |
Exceptional items | 0 | 0 | -10.61 | 0 | 0 | 0 |
Profit before tax | 17.04 | 97.86 | 86.80 | 102.69 | 155.50 | 148.76 |
Net profit before associate | — | — | — | — | 144.57 | 125.93 |
Share of associate (APL) profit | — | — | — | — | 166.10 | 191.45 |
Net profit incl. associate | — | — | 191 | 269 | 310.68 | 317.38 |
Standalone net profit | 13.36 | 85.71 | 79.27 | 92.89 | 141.95 | 124.54 |
Per-share metric (INR)
| Per-share metric (INR) | FY2022 | FY2023 | FY2024 | FY2025 | FY2026 |
|---|---|---|---|---|---|
EPS consolidated, basic = diluted (computed) | — | 7.44 | 10.48 | 12.10 | 12.36 |
EPS standalone, basic = diluted | 3.34 | 3.09 | 3.62 | 5.53 | 4.85 |
Dividend per share | — | — | 2.40 | 2.40 | 2.40 |
Margin / growth (%)
| Margin / growth (%) | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 | FY2026 |
|---|---|---|---|---|---|---|
EBITDA margin (excl. other income) | 15.1 | 17.8 | 31.7 | 36.1 | 42.2 | 37.2 |
PBT margin on revenue | 23.2 | 125.1 | 68.2 | 65.2 | 70.1 | 62.0 |
PAT before associate / revenue | — | — | — | — | 65.2 | 52.5 |
Revenue growth YoY | — | 6.4 | 62.7 | 23.8 | 40.9 | 8.2 |
Cost line (standalone)
| Cost line (standalone) | FY2026 | % of revenue |
|---|---|---|
Cost of materials consumed | 13.88 | 6.0 |
Change in inventories | 2.55 | 1.1 |
Employee benefit expense | 37.44 | 16.1 |
Cost of construction | 60.02 | 25.9 |
Other expenses | 30.35 | 13.1 |
Depreciation | 12.01 | 5.2 |
Finance cost | 1.57 | 0.7 |
Total expenses | 157.81 | 68.0 |
Other income | 72.77 | 31.4 |
PBT | 146.89 | 63.3 |
Tax (current 22.00 + deferred 0.35) | 22.35 | — |
PAT | 124.54 | 53.7 |
Balance Sheet Item Details
| Balance sheet item | 31-Mar-2026 |
|---|---|
Property, plant & equipment | 169.95 |
Capital work-in-progress | 1.50 |
Investment property | 299.59 |
Non-current investments (APL at cost, Paushak at FV, others) | 259.85 |
Other non-current assets | 40.00 |
Inventories (incl. real-estate WIP) | 52.24 |
Current investments | 89.05 |
Trade receivables | 30.21 |
Cash & cash equivalents | 1.10 |
Other bank balances | 1.87 |
Total assets | 957.70 |
Equity share capital | 51.36 |
Other equity | 770.10 |
Total equity | 821.46 |
Long-term borrowings | 6.61 |
Short-term borrowings | 4.03 |
Total debt | 10.64 |
Net debt (debt − cash − bank − current investments) | -81.38 |
Total current assets | 186.85 |
Total current liabilities | 96.31 |
Working capital | 90.54 |
Goodwill & intangibles | 0 |
Cash flow item
| Cash flow item | FY2026 |
|---|---|
Profit before tax | 146.89 |
Operating cash flow before tax | 136.37 |
Income tax paid | 18.97 |
Net cash from operating activities | 117.40 |
Capex — PPE | 38.25 |
Capex — investment property | 38.41 |
Total capex | 76.65 |
Free cash flow (OCF − capex) | 40.75 |
Dividends received (investing) | 62.95 |
Interest received | 1.40 |
Net purchase of investments (16,981.54 − 13,029.30 lakh) | 39.52 |
Net cash used in investing | -52.04 |
Dividends paid | 61.41 |
Repayment of borrowings | 3.81 |
Interest paid | 1.57 |
Buybacks | 0 |
Net cash used in financing | -66.79 |
Net change in cash | -1.43 |
Returns & Leverage Ratios (%) and Financial Ratios (x)
| Ratio | FY2026 standalone | FY2025 consolidated (aggregator) | Comment |
|---|---|---|---|
ROE (%) | 15.2 | 13.28 | Standalone on closing equity; Research360 consolidated |
ROA (%) | 13.0 | 12.41 | Standalone on closing assets |
ROCE (%) | — | 12.4 | Screener (pre-FY2026) |
Current ratio (x) | 1.94 | — | 186.85 / 96.31 |
Debt / equity (x) | 0.013 | — | Effectively debt-free |
Net debt / EBITDA (x) | -0.93 | — | Net cash position |
Interest coverage (x) | 94.6 | — | (PBT + interest) / interest |
Asset turnover (x) | 0.24 | — | Holdco asset base depresses turnover |
Debtor days | 47.5 | 41.7 | FY2026 computed (30.21/231.93×365); Screener prior |
Dividend payout (% of standalone PAT) | 49.4 | 63.8 | 61.6/124.54; Screener 5-yr average |
Region revenue (INR Cr)
| Region revenue (INR Cr) | FY2024 | FY2025 | FY2026 |
|---|---|---|---|
India (real estate, wholly domestic) | 125.74 | 189.67 | 193.40 |
API (domestic + export, split not disclosed) | 31.75 | 32.22 | 46.59 |
Segment Overview — Real Estate
| Segment | India | Export | Comment |
|---|---|---|---|
Real Estate | 100% (Vadodara, Gujarat) | 0% | All projects are in Vadodara |
Share Price & Returns
| Horizon | Return (%) | As of | Source |
|---|---|---|---|
6 months | 10.42 | Oct 2026 (ScanX live widget) | ScanX |
1 year | -2.31 | Oct 2026 (ScanX live widget) | ScanX |
1 year | -7.87 | 14 Feb 2026 | iocharts |
Year-to-date 2026 | -11.54 | mid-2026 (price INR 89.51) | Zonebourse |
Price point (INR) | Date | Source | — |
| 112.12 | ~mid-2025 | Finology | — |
| 95.47 | 14 Feb 2026 | iocharts | — |
| 91.31 | 26 Feb 2026 | Research360 | — |
| 86.87 | 11 Aug 2026 | Univest | — |
| 97.36 | Oct 2026 (ScanX widget at time of research) | ScanX | — |
52-week range | 70.5 – 126 (Screener, 2026 snapshot) | Screener | — |
Valuation Multiples
| Multiple | Alembic Ltd | Basis |
|---|---|---|
P/E (consolidated, FY2026 EPS 12.36) | 7.9x | At INR 97.36 |
P/E (standalone EPS 4.85) | 20.1x | At INR 97.36 |
P/B (consolidated) | ~1.0x | iocharts 0.97 (Feb 2026); Research360 BVPS ~INR 91 |
EV/EBITDA | ~30.5x | iocharts, Feb 2026 (on operating EBITDA ex-associate) |
EV/Sales | ~10.4x | Market cap ~INR 2,500 crore less net cash ~INR 81 crore / revenue INR 240 crore |
Dividend yield | ~2.5% | INR 2.40 / INR 97.36 |
Components
| Component | Value (INR Cr) | Basis |
|---|---|---|
APL stake (56,097,544 × INR 829.65) | 4,654 | APL price 7 Aug 2026 (MoneyWorks4Me) |
Paushak stake (carrying value) | 163 | FVOCI at 31 Mar 2026 |
Net cash & current investments (standalone) | 81 | 31 Mar 2026 |
Real estate + API + power (book: investment property + PPE) | 470 | 31 Mar 2026 book values |
Indicative gross asset value | 5,368 | Sum |
Market capitalisation | ~2,500 | INR 97.36 |
Implied discount to indicative GAV (%) | ~53 | Computed |
Peer Comparison
| Company | Market cap (INR Cr) | P/E (x) | Date | Source |
|---|---|---|---|---|
Alembic Ltd | ~2,500 | 7.9 (consolidated) | Oct 2026 | Computed |
Ganesh Housing | 6,176 | 67.2 | 2026 | Screener |
Arvind SmartSpaces | Not captured | Not captured | — | — |
Alembic Pharma (associate) | ~14,952 | 22.5 | 2026 | Screener |
Dividend metric
| Dividend metric | FY2024 | FY2025 | FY2026 |
|---|---|---|---|
DPS (INR) | 2.40 | 2.40 | 2.40 |
Dividend as % of face value | 120 | 120 | 120 |
Capital Markets
| Item | Status |
|---|---|
Buyback authorisations | None current; last buyback FY2019 |
Debt maturity | Gross debt INR 10.64 crore (LT INR 6.61 crore; ST INR 4.03 crore); no listed debt securities; not a high-value debt-listed entity |
Analyst Conclusions
Guidance and expectations
Alembic Limited provides no guidance and has no published consensus. The most relevant forward indicators are: (a) APL's raised FY2027 outlook (mid-teens revenue growth; US generics mid-to-high teens; 15+ US launches) — positive for associate income, which should exceed FY2026's INR 191.45 crore if APL delivers; and (b) the real-estate delivery calendar, where the next large handovers (Park Crescent, 72 units) fall in FY2028, implying subdued real-estate revenue in FY2027 (Q1 FY2027 RE revenue was flat at INR 37.03 crore).
Bull case
-
Look-through value re-rating: the APL stake alone (~INR 4,654 crore) is roughly 1.9x Alembic Limited's market cap; any catalyst (simplification, higher payout, value-unlocking) could compress the ~50% discount.
-
APL earnings momentum: Q1 FY2027 APL PAT +12% and revenue +26%, with guidance raised, should lift associate income and consolidated EPS beyond INR 12.36.
-
Cash-rich, debt-free operating base: INR 81 crore net cash plus INR 299.59 crore investment property supports dividends, rental growth and new project launches without dilution.
Bear case
-
Structural holdco discount: 70.88% promoter control, sparse disclosure and absence of a value-unlocking mandate may keep the discount permanent.
-
Operating stagnation: pre-associate PAT fell 12.9% in FY2026 and ~12% in Q1 FY2027; real-estate revenue has plateaued at ~INR 190 crore with small project sizes.
-
Investment value erosion: the Paushak stake's carrying value declined sharply in FY2026 (OCI −INR 94.65 crore), and APL itself is exposed to US generic pricing risk.
Catalysts and monitorables (next 12 months)
| Catalyst / monitorable | Expected timing | Why it matters |
|---|---|---|
| Q2 FY2027 results (Alembic Ltd and APL) | Oct–Nov 2026 | APL dividend timing; RE handovers; API trajectory |
| APL US launches and USFDA inspection outcomes | Ongoing FY2027 | Associate income |
| Park Crescent construction progress (RERA quarterly updates) | Quarterly | FY2028 revenue visibility |
| New RERA registrations in Alembic City | Any time | Pipeline replenishment |
| Board refresh (independent director vacancy) | FY2027 | Governance quality |
| Disclosure improvements under new MD | FY2027 AGM/annual report | Could narrow discount |
| Paushak share price / any stake transactions | Ongoing | OCI and capital allocation |
| FY2027 dividend decision | May 2027 | Payout sustainability |
Analyst verdict
Alembic Limited is a textbook Indian promoter holding company: a 119-year-old corporate shell whose economic value now resides overwhelmingly in a minority stake in a far larger listed pharmaceutical business. Its own operations — a land-based Vadodara real-estate franchise and a sub-scale API unit — are profitable and conservatively financed, but they are small, lumpy and opaquely disclosed. FY2026 illustrated the pattern precisely: revenue grew a modest 8.2% to INR 240 crore, the company's own net profit fell 13%, and yet consolidated earnings edged up 2% to INR 317 crore entirely because the associate APL earned more.
The valuation arithmetic is the investment case. At roughly INR 97 per share, the market capitalisation of about INR 2,500 crore is around half the market value of the APL stake alone, before attributing anything to the real-estate assets (INR 470 crore at book), the Paushak stake or net cash. On consolidated earnings the stock trades below 8x — cheap by any absolute measure — and offers a ~2.5% dividend yield that is effectively pre-funded by APL's dividend.
The difficulty is that discounts of this kind in Indian family holdcos are durable rather than temporary. Nothing in the filings signals a value-unlocking agenda: there is no buyback, no stated payout policy beyond a flat INR 2.40, no investor communication, and real-estate growth is constrained by small, slow project phases. The leadership transition to Udit Amin is the one genuine wildcard; better disclosure or capital-allocation changes could shift sentiment.
For investors needing a catalyst, the operating business is too small and the governance structure too closed to expect rapid convergence toward look-through value. Monitor APL's FY2027 delivery and any signal of strategic change from the new MD.
Unlock Company Financials
Unlock this company profile to view its financial data.
View Subscription PlansExecutive Leadership
Board of Directors
| Name | Title | Category | Born / age | Board tenure | Background | Source |
|---|---|---|---|---|---|---|
Chirayu R. Amin | Chairman | Non-Executive, Non-Independent (Promoter) | 4 Dec 1946 / 79 | Director since 20 Aug 1967 | MBA (USA); with company since 1983; Executive Chairman of APL; director of Paushak, Shreno, Nirayu; past President of FICCI and ICC India; past VP of BCCI | NSE governance filing Apr 2026; company website |
Udit C. Amin | Managing Director | Executive (Promoter family) | 14 May 1980 / 46 | Director since 24 Apr 2013; MD w.e.f. 1 Oct 2025 (also MD from Mar 2016) | Economics (international trade), University of Michigan; previously Director & President – Operations; director of Paushak, Shreno, Nirayu | NSE governance filing; website; AR 2015-16 |
Malika C. Amin | Non-Executive Director (MD & CEO until 31 Dec 2025) | Non-Executive, Non-Independent | 22 Oct 1954 / 71 | Since 2 Jul 1988 | MA; whole-time director of Shreno; director of Suvid Hospitals | NSE governance filing; website |
Jain Parkash | Non-Executive Director | Non-Executive, Non-Independent | — | — | Ex-Punjab Chemicals & Crop Protection and Tagros Chemicals; whole-time director of Paushak | Website; Muthoot Securities |
Rati Desai | Independent Director | Independent | — | — | Also director of Alembic City Ltd (per website note) | Muthoot Securities; website |
Girish Hirode | Independent Director | Independent | — | — | — | Muthoot Securities |
Geeta Goradia | Independent Director | Independent | — | — | — | Muthoot Securities |
Mayur Jadeja | Independent Director | Independent | — | — | — | Muthoot Securities |
Sanjeev Shah | Independent Director | Independent | — | — | — | Muthoot Securities |
Sameer Khera | Independent Director | Independent | — | — | Manufacturing management (SPJIMR); MD of SEE Linkages | Website |
Mayank Amin | Independent Director (deceased) | Independent | — | Appointed ~2023 | Website carries an intimation of his demise (date not captured) | Website; AR 2023 notice |
Keval Thakkar | Company Secretary & Compliance Officer | KMP | — | 2,026 | — | Board intimation May 2026 |
CFO | — | KMP | — | — | Not identified in sources reviewed | — |
“—” = not publicly disclosed.
Executive Leadership Team
| Executive | Stock |
|---|---|
Udit Amin (MD) | Nil (no ESOP disclosed) |
Governance Overview
| Governance attribute | Status |
|---|---|
Chair / CEO separation | Formally separate (Non-Executive Chairman; MD), but both roles held by father and son |
Committees | Audit, Nomination & Remuneration, Stakeholders' Relationship, CSR (statutory); Udit Amin is a committee member since 6 May 2014 (committee name per filing) |
Related-party intensity | High: material transactions with APL (sales INR 28.02 crore H2 FY2026; omnibus approval up to INR 80.26 crore), Alembic City Ltd (INR 21.36 crore), Paushak, Shreno, Nirayu (royalty INR 0.16 crore paid to Nirayu) |
RPT policy | Updated 7 Feb 2025; published on website |
Audit opinion | Unmodified, FY2026 (CNK & Associates LLP) |
Board & Management Changes
| Date | Change | Context |
|---|---|---|
1 Oct 2025 | Udit Amin designated Managing Director | Generational transition within the promoter family |
1 Jan 2026 | Malika Amin relinquishes MD & CEO; continues as Non-Executive Director | Completes handover to Udit Amin |
2025–2026 | Demise of Independent Director Mayank Amin | — |
| 2026 | Keval Thakkar signs as Company Secretary | Earlier CS: Drigesh Mittal |
Major Shareholders
| Shareholder class | Stake (%) | Date | Source |
|---|---|---|---|
Promoter & promoter group | 70.88 | Dec 2024 (unchanged through 2025 per INDmoney "promoter holding unchanged") | Finology; Zerodha |
— of which Nirayu Private Limited | ≥41.11 (2018; increased via creeping acquisitions) | Mar 2018 | Annual Return 2017-18 |
— of which Shreno Limited | 13.69 | Mar 2019 | Annual Return 2018-19 |
Promoter pledge | 0.00 | Dec 2024 | Finology |
Public & institutions | 29.12 | Dec 2024 | Derived |
Competitive Landscape
Competitors by Segment
| Segment | Competitor | Positioning |
|---|---|---|
Real estate (Gujarat) | Arvind SmartSpaces (Ahmedabad, Lalbhai Group) | Multi-city, JV/development-partnership model; HDFC Capital platform |
Real estate (Gujarat) | Ganesh Housing Corporation (Ahmedabad) | Land-rich, very high-margin; residential, commercial, IT parks |
Real estate (Vadodara) | Local Vadodara developers (unlisted) | Direct competition for premium buyers; share data not available |
Real estate (Gujarat) | Goyal & Co., Shivalik Group (unlisted) | Ahmedabad-centred premium developers |
API | Aarti Drugs | Large-volume domestic API maker |
API | Solara Active Pharma Sciences | Pure-play API exporter |
API | Granules India | Large-volume paracetamol/metformin API |
API (fermentation) | Concord Biotech | Fermentation-based APIs (immunosuppressants) |
Holding-company peers | Bombay Burmah Trading, Kama Holdings, Tata Investment Corporation, Bajaj Holdings, Maharashtra Scooters | Listed holdcos trading at discounts to look-through value |
Peer Comparison FY2026
| Metric | Alembic Ltd | Arvind SmartSpaces | Ganesh Housing | Alembic Pharma (associate, context) |
|---|---|---|---|---|
Revenue from operations | 239.99 | 564.05 | 511.37 | Q1 FY2027: 2,149.77 |
Revenue growth YoY (%) | 8.2 | -20.9 | -46.7 | Q1 FY2027: 25.7 |
Operating profit | 89.37 | 172.33 | 449.70 | Q1 FY2027 EBITDA pre-R&D: 523 |
Operating margin (%) | 37.2 | 30.6 | 87.9 | 24 (pre-R&D) |
Net profit | 317.38 | 103.38 | 316.26 | Q1 FY2027: 173.07 |
R&D intensity (%) | — | Not applicable | Not applicable | Not captured |
“—” = not publicly disclosed.



